Lisa A. Jackson, MD, MPH
“Kaiser Permanente Washington gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”
Lisa A. Jackson, MD, MPH
Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine
Biography
Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.
Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.
Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.
Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.
After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.
Research interests and experience
Vaccines & Infectious Diseases
Vaccine safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia
Recent publications
Jackson LA, Alexander ER, DeBolt CA, Swenson PD, Boase J, McDowell MG, Reeves MW, Wenger JD. Evaluation of the use of mass chemoprophylaxis during a school outbreak of enzyme type 5 serogroup B meningococcal disease. Pediatr Infect Dis J. 1996;15(11):992-8. PubMed
Jackson LA, Campbell LA, Kuo CC, Grayston JT. Detection of Chlamydia pneumoniae in atheroma specimens. J Infect Dis. 1996;174(4):893-6. PubMed
Jackson LA, Farley MM, Schuchat A. Adult group B steptococcal disease. Ann Intern Med. 1996;125(2):152-3. PubMed
Jackson LA, Stewart LK, Solomon SL, Boase J, Alexander ER, Heath JL, McQuillan GK, Coleman PJ, Stewart JA, Shapiro CN. Risk of infection with hepatitis A, B, or C, cytomegalovirus, measles and varicella among child care providers. Pediatr Infect Dis J. 1996;15(7):584-9. PubMed
Jackson LA, Spach DH. Emergence of Bartonella quintana infection among homeless persons. Emerg Infect Dis. 1996;2(2):141-4. PubMed
Jackson LA, Spach DH, Kippen DA, Sugg NK, Regnery RL, Sayers MH, Stamm WE. Seroprevalence to Bartonella quintana among patients at a community clinic in downtown Seattle. J Infect Dis. 1996;173(4):1023-6. PubMed
Imrey PB, Jackson LA, Ludwinski PH, England AC 3rd, Fella GA, Fox BC, Isdale LB, Reeves MW, Wenger JD. An outbreak of serogroup C meningococcal disease associated with campus bar patronage. Am J Epidemiol. 1996;143(6):624-30. PubMed
Jackson LA, Grayston JT. Chlamydia pneumoniae and mycoplasma pneumoniae infections. Curr Opin Infect Dis. 1996;9:89-93. PubMed
Kuo CC, Jackson LA, Lee A, Grayston JT. In vitro activities of azithromycin, clarithromycin, and other antibiotics against C. pneumoniae. Antimicrobial Agents Chemother. 1996;40:2669-2670. PubMed
Jackson LA, Grayston JT. Chlamydia pneumoniae (TWAR). In: Schlossberg D, ed. Current Therapy of Infectious Disease. St. Louis: Mosby -Year Book, Inc., 1996:398-399. PubMed
News
Researchers begin trial for high-dose flu vaccine
KPWHRI is seeking volunteers ages 50 to 64 who have not received this season’s flu vaccine to join the trial.
News
Vaccine program recruiting volunteers in Seattle area
KPWHRI’s vaccine registry was the first to enroll participants in a clinical trial of a COVID-19 vaccine.
News
Clinical trial will evaluate mpox vaccine for adolescents
The NIH-sponsored trial will help inform decisions about vaccine approval for 12- to 17-year-olds.
Volunteers needed
Researchers begin trial for mRNA flu vaccine
The investigational vaccine is in the third phase of trials and targets flu strains expected to circulate this winter.
Research
New study confirms safety of shingles vaccine
KPWHRI researchers analyzed data from more than 640,000 vaccine doses to understand risk of severe reactions.
Land Acknowledgment
Our Seattle offices sit on the occupied land of the Duwamish and by the shared waters of the Coast Salish people, who have been here thousands of years and remain. Learn about practicing land acknowledgment.